Investors and interested observers can access the live discussion via the company’s investor relations portal. For those joining by phone, the conference line is available at 1-833-461-5787 using the access code 762246460. Following the live event, Nuvation Bio plans to maintain an archived recording on its website for a period of 90 days.

Founded in 2018 by industry veteran David Hung, the company continues to focus on complex cancer therapies, including its ROS1 inhibitor taletrectinib and the brain-penetrant IDH1 inhibitor safusidenib. The firm maintains a global presence with offices across New York, San Francisco, Boston, and Shanghai as it pushes forward its current drug-drug conjugate research programs.